Acta Med. 2019, 62: 52-57

https://doi.org/10.14712/18059694.2019.46

The Assessment of Serum Drug Levels to Diagnose Non-Adherence in Stable Chronic Heart Failure Patients

Radek Peloucha,b, Viktor Voříšekc, Věra Furmanovác, Miroslav Solařa,b

aDepartment of Internal Medicine, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
b1st Department of Internal Medicine – Cardioangiology, University Hospital Hradec Králové, Czech Republic
cInstitute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Czech Republic

Received January 6, 2019
Accepted February 17, 2019

References

1. Van Riet EES, Hoes1 AW, Wagenaar KP, Limburg A, Landman MAJ and Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. European Journal of Heart Failure 2016; 18: 242–52. <https://doi.org/10.1002/ejhf.483>
2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 2016; 37: 2129–200. <https://doi.org/10.1093/eurheartj/ehw128>
3. Riles EM, Jain AV, Fendrick AM. Medication Adherence and Heart failure. Curr Cardiol Rep 2014; 16: 458. <https://doi.org/10.1007/s11886-013-0458-z>
4. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. Journal of Hypertension 2017; 35: 1133–44. <https://doi.org/10.1097/HJH.0000000000001299>
5. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes. Circulation 2007; 116: 737–44. <https://doi.org/10.1161/CIRCULATIONAHA.106.669101>
6. Fitzgeralg AA, Powers JD, Ho PM, et al. Impact of Medication Nonadherence on Hospitalizations and Mortality in Heart Failure. J Cardiac Fail 2011; 17: 664–9. <https://doi.org/10.1016/j.cardfail.2011.04.011>
7. Zhang Y, Wu SH, Fendrick AM, Baicker K. Variation in Medication Adherence in Heart Failure. JAMA Intern Med 2013; 173(6): 468–70. <https://doi.org/10.1001/jamainternmed.2013.2509> <PubMed>
8. Yoo BS, Oh J, Hong BK, et al. SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): A Multi- Center, Retrospective, Observational Study. PLoS ONE 2014; 9: 1–7.
9. Hood SR, Giazzon AJ, Seamon G, et al. Association Between Medication Adherence and the Outcomes of Heart Failure. Pharmacotherapy 2018; 38(5): 539–45. <https://doi.org/10.1002/phar.2107>
10. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: doubleblind, randomised, controlled clinical trial. Lancet 2005; 366: 2005–11. <https://doi.org/10.1016/S0140-6736(05)67760-4>
11. Van Onzenoort HA, Verberk WJ, Kessels AG, et al. Assessing Medication Adherence Simultaneously By Electronic Monitoring And Pill Count In Patients With Mild-To-Moderate Hypertension. Am J Hypertens 2010; 23(2): 149–54. <https://doi.org/10.1038/ajh.2009.207>
12. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult- to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertension Research 2011; 34: 87–90. <https://doi.org/10.1038/hr.2010.183>
13. Florczak E, Tokarczyk B, Warchoł-Celińska E, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESISTPOL study. Pol Arch Med Wewn 2015; 125(1–2): 65–72.
14. Avataneo V, De Nicolò A, Rabbia F, et al. Therapeutic drug monitoringguided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. Br J Clin Pharmacol 2018; 84: 2535–43. <https://doi.org/10.1111/bcp.13706> <PubMed>
15. Strauch B, Petrak O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension 2013; 31: 2455–61. <https://doi.org/10.1097/HJH.0b013e3283652c61>
16. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Journal of Hypertension 2013; 31: 766–74. <https://doi.org/10.1097/HJH.0b013e32835e2286>
17. Tomaszewski M, White Ch, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spektrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100(11): 855–61. <https://doi.org/10.1136/heartjnl-2013-305063> <PubMed>
18. Šíma M, Vodička M, Marešová V, Šálek T, Čabala R, Slanař O. Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int J Clin Pharm 2017; 39: 1095–100. <https://doi.org/10.1007/s11096-017-0522-7>
19. Pandey A, Raza F, Velasco A, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment–resistant hypertension. Journal of the American Society of Hypertension 2015; 9: 420–6. <https://doi.org/10.1016/j.jash.2015.04.004>
20. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography- single stage or tandem mass spectrometry (LC-MS or LC-MS/ MS) relevant to clinical and forensic toxicology. Clin Biochem 2005; 38: 310–8. <https://doi.org/10.1016/j.clinbiochem.2005.01.014>
21. Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Loukas YL. Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry. Anal Bioanal Chem 2007; 387: 593–601. <https://doi.org/10.1007/s00216-006-0990-4>
22. Solar M, Pelouch R, Vorisek V, Furmanova V, Ceral J. Serum drug levels to diagnose non-adherence in acute decompensated heart failure. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(2): 244–7. <https://doi.org/10.5507/bp.2016.031>
23. Roebuck MCh, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Affairs 2011; 30(1): 91–9. <https://doi.org/10.1377/hlthaff.2009.1087>
24. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008; 62(2): 338–51. <https://doi.org/10.1111/j.1742-1241.2007.01683.x> <PubMed>
25. Zullig LL, Mendys P, Bosworth HB. Medication adherence: A practical measurement selection guide using case studies. Patient Education and Counseling 2017; 100: 1410–4. <https://doi.org/10.1016/j.pec.2017.02.001> <PubMed>
26. Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension 2017; 70: 1042–8. <https://doi.org/10.1161/HYPERTENSIONAHA.117.09631> <PubMed>
27. Schoonhoven AV, Asselt ADI, Tomaszewski M, et al. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension 2018; 72: 1117–24. <https://doi.org/10.1161/HYPERTENSIONAHA.118.11227>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive